www.klinickafarmakologie.cz / Klin Farmakol Farm. 2025;39(1):34-43 / KLINICKÁ FARMAKOLOGIE A FARMACIE 43 HLAVNÍ TÉMA Lékové interakce DOAC a protizáchvatových léků 24. Chin PKL, Wright DFB, Zhang M, et al. Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C. Drugs R D. 2014;14(2):113-123. 25. King PK, Stump TA, Walkama AM, et al. Management of Phenobarbital and Apixaban Interaction in Recurrent Cardioembolic Stroke. Ann Pharmacother. 2018;52(6):605-606. 26. Dagan G, Perlman A, Hochberg-Klein S, et al. Managing Direct Oral Anticoagulants in Patients With Antiepileptic Medication. Can J Cardiol. 2018;34(11):153.4e1-1534.e3. 27. Eyal S, Lamb JG, Smith-Yockman M, et al. The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver. Br J Pharmacol. 2006;149(3):250-260. 28. Červený L, Švecová L, Anzenbacherová E, et al. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos. 2007;35(7): 1032-1041. 29. Olaizola I, Brodde MF, Kehrel BE, Evers S. The Impact of Levetiracetam and Valproate on Platelet Functions-A Double-Blind, Placebo-Controlled Crossover Study. J Clin Med. 2023;12(3):933. 30. Langenbruch L, Meuth SG, Wiendl H, et al. Clinically relevant interaction of rivaroxaban and valproic acid – A case report. Seizure. 2020;80:46-47. 31. SPC ČR: Depakine Chrono® (kyselina valproová), Sanofi s.r.o., 7/2024. [Internet]. Available from: https://sukl.gov.cz/ verejnost/leciva/. 32. SPC ČR: Xarelto® (rivaroxaban), Bayer Pharma, 9/2024. [Internet]. Available from: https://www.ema.europa.eu/documents/product-information/xarelto-epar-product-information_cs.pdf. 33. SPC ČR: Keppra (levetiracetam), UCB Pharma 1/2025. [Internet]. Available from: https://www.ema.europa.eu/cs/ documents/product-information/keppra-epar-product-information_cs.pdf. 34. Mavri A, Ilc S. The efficacy of direct oral anticoagulants in patients on concomitant treatment with levetiracetam. Sci Rep. 2023;13(1):9257. 35. Giner-Soriano M, Marsal JR, Gomez-Lumbreras A, et al. Risk of ischaemic stroke associated with antiepileptic drugs: a population-based case-control study in Catalonia. BMC Neurol. 2021;21(1):208. 36. Sáez-Torres de Vicente M, Puig PM, Toresano LV, et al. Ischemic stroke due to possible interaction of rivaroxaban with primidone in a patient with atrial fibrillation. Med Clin (Barc) 2021;156(5):255-256. 37. Manis MM, Petersen K, Roberts MZ, Kyle JA. Managing the Drug-Drug Interaction With Apixaban and Primidone: A Case report. Hosp Pharm. 2023;58(4):345-349. 38. Andreasen A, Brosen K, Damkier P. A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4. Epilepsia. 2007; 48(3):490-496. 39. Serra W, Calzi ML, Coruzzi P. Left Atrial Appendage Thrombosis During Therapy with Rivaroxaban in Elective Cardioversion for Permanent Atrial Fibrillation. Clin Pract. 2015;5(3):788. 40. Robinson ZS, Arvin JP, Madding KL, et al. Rivaroxaban Failure in a Patient Taking Oxcarbazepine. Ann Pharmacother. 2021;55(10):1302-1303. 41. SPC ČR: Diacomit® (spiripentol), Biocodex, 7/2024 https:// www.ema.europa.eu/cs/documents/product-information/ diacomit-epar-product-information_cs.pdf. 42. Kerr BM, Martinez-Lage JM, Viteri C, et al. Carbamazepine dose requirements during stiripentol therapy: influence of cytochrome P-450 inhibition by stiripentol. Epilepsia. 1991;32(2):267-274. 43. SPC ČR: Fycompa (perampanel), Eisai 5/2023. [Internet]. Available from: https://www.ema.europa.eu/cs/documents/product-information/fycompa-epar-product-information_cs.pdf. 44. SPC ČR: Inovelon® (rufinamid), Eisai GmbH, 12/2023. [Internet]. Available from: https://www.ema.europa.eu/cs/documents/product-information/inovelon-epar-product-information_cs.pdf. 45. Stölberger C, Finsterer J, Schneider B. Interactions between antiepileptic drugs and direct oral anticoagulants for primary and secondary stroke prevention. Expert Opin Drug Metab Toxicol. 2024;20(5):359-376. 46. Greene SA, Kwak C, Kamin M, et al. Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects. Clin Transl Sci. 2022;15(4):899-911. 47. SPC ČR: Ontozry® (cenobamát), Angelini Pharma, 12/2024. [Internet]. Available from: https://www.ema.europa.eu/cs/ documents/product-information/ontozry-epar-product- -information_cs.pdf. 48. Bansal S, Zamarripa CA, Spindle TR, et al. Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants. Clin Pharmacol Ther. 2023; 114(3):693-703. 49. SPC ČR: Epidyolex® (kanabidiol), 9/2024. Jazz Pharmaceuticals Ireland. [Internet]. Available from: https://www.ema.europa.eu/cs/documents/product-information/epidyolex-epar- -product-information_cs.pdf. 50. Martin P, Czerwinski M, Limaye PB, et al. In vitro evaluation suggests fenfluramine and norfenfluramine are unlikely to act as perpetrators of drug interactions. Pharmacol Res Perspect. 2022;10(3):e00959. 51. SPC ČR: Fintepla® (fenfluramin), UCB Pharma 8/2024. [Internet]. Available from: https://www.ema.europa.eu/cs/ documents/product-information/fintepla-epar-product- -information_cs.pdf. 52. Grymnoprez M, Carnoy L, Capiau A, et al. Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2023;9(8):722-730. … nenechte si ujít aktuální informace o možnostech medicínského vzdělávání FACEBOOK https://www.facebook.com/ SolenMedicalEducation/ @SolenMedicalEducation LINKEDIN https://www.linkedin.com/ company/solen-medical-education/ #solenmedicaleducation X https://twitter.com/ MedicalSolen @MedicalSolen ODEMČENÉ AKTUÁLNÍ ČLÁNKY PŘEHLED O VZDĚLÁVACÍCH AKCÍCH UPOZORNĚNÍ NA ZVÝHODNĚNÉ CENY SOUTĚŽE O VSTUPENKY NA KONGRESY INFORMACE O ON LINE KURZECH NOVINKY V E SHOPU … a mnoho dalšího
RkJQdWJsaXNoZXIy NDA4Mjc=